Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted

Number Of 2021 Offerings Exceeded 2020, But Returns Faltered

Executive Summary

Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active. 

You may also be interested in...



BIO 2022: ‘Limitless’ Innovation Is Harder With Limited Cash

The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm. 

Volatility And Valuations Among Factors Weighing On Pharma Deal Making

Market volatility, persistently high valuations, inflation and interest rates are among the issues sidetracking broader M&A, experts say.

Finance Watch: Biopharma IPO Market Silence Continues In The US

Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs. 

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel